Portal de Periódicos da CAPES

Antithrombotic Therapy in Atrial Fibrillation

2001; Elsevier BV; Volume: 119; Issue: 1 Linguagem: Inglês

10.1378/chest.119.1_suppl.194s

1931-3543

Gregory W. Albers, James E. Dalen, Andreas Laupacis, Warren J. Manning, Pelle Trier Petersen, Daniel E. Singer,

Antiplatelet Therapy and Cardiovascular Diseases

Atrialfibrillation (AF) is the most common sustained arrhythmia and is animportant independent risk factor for stroke. AF is present in > 2million people in the United States.1 Its prevalencebegins to increase in both genders after age 40 years and rises rapidlyafter age 65 years.2, 3, 4, 5 AF is particularly common in theelderly, reaching a prevalence of roughly 10% in those > 80 yearsold.2, 3, 4, 5 The median age of patients with AF isapproximately 75 years.1 The condition is more prevalentin men than in women.